LAX.SH
BLISS GVS PHARMA LTD·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
642.7
+4.99%52W Range
Market Cap
₹6,830.31 Cr
Traded: ₹15.66 Cr (0.23%) 0.0x
Free Float: ₹3,187.70 Cr (0.49% of FF traded)
Volume · 60D trend
2.46 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | +5.0% | +14.0% | +23.0% | -- | +55.0% | Accelerating |
| Return | +10.0% | +20.0% | +54.0% | +136.0% | -- | Accelerating |
| Sales | +5.0% | +10.0% | +7.0% | -- | +15.0% | Stable |
| ROE | +11.0% | +9.0% | +10.0% | -- | -- | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 286 | 257 | 218 | 244 | 207 | 198 | 210 | 218 | 184 | 198 | 201 | 212 | 160 | 185 | 206 | 172 |
| Expenses | 209 | 213 | 183 | 201 | 166 | 177 | 181 | 176 | 149 | 170 | 157 | 158 | 135 | 179 | 158 | 148 |
| Operating Profit | 76 | 44 | 35 | 43 | 41 | 21 | 30 | 41 | 34 | 28 | 44 | 54 | 24 | 6 | 48 | 25 |
| Other Income | 10 | 11 | 16 | 8 | 35 | 12 | 15 | 5 | 4 | -24 | 5 | 13 | 5 | 3 | 6 | 2 |
| Interest | 1 | 2 | 1 | 3 | 5 | 2 | 1 | 4 | 2 | 2 | 2 | 1 | 1 | 5 | 1 | 2 |
| Depreciation | 10 | 9 | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 5 |
| Profit Before Tax | 75 | 45 | 41 | 41 | 63 | 23 | 36 | 36 | 30 | -4 | 40 | 59 | 22 | -1 | 47 | 20 |
| Tax % | 32.0% | 18.0% | 39.0% | 30.0% | 30.0% | 29.0% | 29.0% | 28.0% | 26.0% | 24.0% | 27.0% | 27.0% | 34.0% | -561.0% | 37.0% | 21.0% |
| Net Profit | 51 | 37 | 25 | 29 | 44 | 17 | 26 | 26 | 22 | -5 | 29 | 43 | 14 | 3 | 30 | 16 |
| Exceptional Items | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | -29 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 4.7 | 3.4 | 2.2 | 2.6 | 4.1 | 1.5 | 2.3 | 2.3 | 2.0 | -0.9 | 2.6 | 4.0 | 1.4 | 0.3 | 2.7 | 1.3 |
| Sales Growth (YoY) | 37.6% | 29.8% | 3.7% | 12.3% | 13.0% | -0.1% | 4.8% | 2.7% | 15.1% | 7.2% | -2.4% | 22.9% | -15.4% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 17.9% | -10.7% | 17.9% | 4.5% | -5.7% | -3.7% | 18.5% | -7.1% | -1.5% | -5.2% | 32.5% | -13.5% | -10.2% | 19.8% | -- |
| OP Growth (YoY) | 85.4% | 109.5% | 16.7% | 4.9% | 20.6% | -25.0% | -31.8% | -24.1% | 41.7% | 366.7% | -8.3% | 116.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 72.7% | 25.7% | -18.6% | 4.9% | 95.2% | -30.0% | -26.8% | 20.6% | 21.4% | -36.4% | -18.5% | 125.0% | 300.0% | -87.5% | 92.0% | -- |
| Profit Growth (YoY) | 16.0% | 129.0% | 4.0% | 12.0% | 108.0% | 34.0% | -14.0% | -43.0% | 41.0% | 248.0% | -1.0% | 205.0% | -43.0% | -83.0% | 148.1% | -34.9% |
| EPS Growth (YoY) | -- | 128.6% | -2.6% | 11.7% | 107.1% | 269.0% | -14.4% | -43.0% | 39.7% | -371.9% | -1.5% | 204.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 52.7% | -14.7% | -36.8% | 177.6% | -35.0% | -2.2% | 17.3% | 326.4% | -132.9% | -34.8% | 187.2% | 340.6% | -88.1% | 101.5% | -- |
| OP Margin | -- | 17.1% | 16.1% | 17.6% | 19.8% | 10.6% | 14.3% | 18.8% | 18.5% | 14.1% | 21.9% | 25.5% | 15.0% | 3.2% | 23.3% | 14.5% |
| Net Margin | -- | 14.4% | 11.5% | 11.9% | 21.3% | 8.6% | 12.4% | 11.9% | 12.0% | -2.5% | 14.4% | 20.3% | 8.8% | 1.6% | 14.6% | 9.3% |
| Material Cost % | -- | 44.1% | 46.6% | 48.3% | 44.3% | 50.2% | 54.3% | 52.8% | 46.4% | 48.2% | 51.1% | 47.1% | 52.9% | 59.0% | 49.3% | 55.5% |
| Employee Cost % | -- | 14.1% | 16.5% | 13.7% | 14.9% | 14.3% | 14.1% | 12.6% | 14.4% | 12.4% | 12.1% | 11.0% | 14.7% | 12.2% | 10.8% | 12.2% |
| P/S | 6.80 | 5.59 | 3.34 | 2.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 49.98 | 40.06 | 26.51 | 20.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.73 | 4.34 | 2.56 | 1.98 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Please find enclosed herewith the newspaper publication regarding the dispatch of Postal Ballot Notice.
Please find enclosed herewith Postal Ballot Notice dated September 28, 2026 ("Notice") alongwith the Explanatory Statement for seeking approval of the members of the Company by way of remote ....
We would like to inform you that the ESOP Allotment Committee at its meeting held today i.e. October 15, 2026 has approved the allotment of 53,500 equity shares of the face value of Re ....
Please find enclosed herewith the disclosure under Regulation 31A (10) of the SEBI Regulations in relation to re-classification from the "promoter and promoter Group category" to the "public" category
Please find enclosed herewith the newspaper advertisement published regarding the Extension of Special Window for Re-Lodgement of Transfer Requests of Physical Shares.
Please find enclosed herewith the certificate under Regulation 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended September 30, 2026.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anupam Rasayan India Ltd
Please find enclosed herewith the outcome of the Board Meeting held today i.e. Thursday, October 01, 2026 through Video Conferencing or Other Audio Visual Means.
Please find enclosed herewith the Intimation for the Closure of the Trading Window w.e.f. Thursday, October 01, 2026.
Please find enclosed herewith Outcome of Board Meeting held on September 28, 2026, pursuant to the consummation of the transaction contemplated in the share purchase agreement dated May 23, 2026.
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/10/2026 ,inter alia, to consider and approve Please find enclosed herewith ....
Please find enclosed herewith the outcome of the Postal Ballot along with the Scrutinizer''s Report and Voting Results.
Please find enclosed herewith the Disclosure of Voting Results of the Postal Ballot along with the Scrutinizer''s Report.
We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held on today i.e. September 04, 2026 has approved the allotment of 55,250 equity shares of ....
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post-Offer Advertisement in accordance with Regulation 18(12) of the Securities and Exchange Board of ....
Please find enclosed herewith the Newspaper Publication regarding the extension of the Special Window for Re-Lodgement of Transfer Request of Physical Shares.
Please find enclosed herewith the Newspaper Publication regarding the publication of the advertisement for the Postal Ballot Notice.
Please find enclosed herewith the Postal Ballot Notice ("Notice") dated August 12, 2026, alongwith the Explanatory Statement for seeking approval of Members of the Company by way of remote ....
Please find enclosed herewith the copies of newspaper advertisement published regarding the extract of statement of Un-audited Standalone and Consolidated Financial Results of the Company ....
Please find enclosed herewith the outcome of Members of the Nomination and Remuneration Committee of Bliss GVS Pharma Limited ("the Company")in its meeting held today i.e. on August 12, ....
We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") with ....
We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026, through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"), with ....
We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. August 11, 2026 has approved the allotment of 31, 250 equity shares of the face ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of the Securities and Exchange Board of ....
Please find attached detailed intimation regarding resignation of Mr. Sachin Saboo, Senior Management Personnel of the Company, pursuant to Regulation 30 of SEBI (Listing Obligations and ....
Please find enclosed herewith the Notice sent to shareholders w.r.t. the transfer of Unclaimed Final Dividend 2018-2019 and its corresponding shares to the IEPF Authority.
Please find attached copies of the newspaper publications containing recommendation of the Committee of Independent Directors.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Clarus Capital I & Others
Please find enclosed herewith the Newspaper publication regarding Notice to Shareholders for Transfer of Unclaimed Final Dividend 2018-2019 and its corresponding Equity Shares to IEPF.
Please find attached the intimation of recommendations by the Committee of Independent Directors pursuant to Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) ....
Letter of Offer dated July 18, 2026 received from SBI Capital Markets Limited, the manager to the Open Offer appointed by Anupam Rasayan India Limited along with PAC.
Addendum to Public Announcement and Detailed Public Statement for the Open Offer made by Anupam Rasayan Limited, the acquirer for the addition of PAC.
Please find enclosed herewith the details of KMPs for reporting Disclosure of Material Events to Stock Exchanges.
Please find attached herewith the proceedings of 41st Annual General Meeting of Bliss GVS Pharma Limited.
Please find enclosed herewith the Voting Results alongwith the Scrutinizer Report for the 41st Annual General Meeting of the Company held on Wednesday, July 15, 2026.
We like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. July 07, 2026 has approved the allotment of 1,87,750 equity shares of the face value ....
Enclosed herewith is the intimation regarding the Change in Management of the Company.
Please find enclosed herewith the Certificate under Regulation 74(5) of the SEBI (D&P) Regulations 2018, for the quarter ended June 30, 2026.
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that based on the recommendation ....
Please find enclosed herewith the Intimation regarding the closure of the Trading Window for the quarter ended June 30, 2026.
Please find enclosed herewith the Newspaper Advertisement published regarding Notice of 41st Annual General Meeting, E-voting and Book Closure Information.
Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), please find ....
Please find enclosed herewith the Notice of 41st AGM of Bliss GVS Pharma Limited ("the Company") scheduled to be held on Wednesday, July 15, 2026, at 11:00 A.M. (IST) through VC/OAVM. The ....
Please find enclosed herewith the intimation for the Book Closure for the purpose of 41st Annual General Meeting of the Company.
Please find enclosed herewith the intimation regarding the Fixation of the record date for the payment of the final dividend for the financial year ended March 31, 2026.
Please find enclosed herewith the Newspaper publication regarding the 41st Annual General Meeting of the Company.
Annual Reports
15Credit Ratings
6Held by ETFs
1 ETFs hold BLISSGVS · sorted by weight
Held by Mutual Funds
2 schemes hold BLISSGVS · sorted by weight